AREXVY’s Expanded Indication Approval

The Therapeutic Goods Administration (TGA) has approved an expanded indication for AREXVY, now including adults aged 50-59 who are at increased risk of respiratory syncytial virus (RSV) disease.

The official indication now reads as follows:

AREXVY is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:

  • Adults aged 60 years and older.
  • Adults aged 50 through 59 years who are at increased risk for RSV disease.
Share AREXVY’s Expanded Indication Approval on Facebook Share AREXVY’s Expanded Indication Approval on Twitter Share AREXVY’s Expanded Indication Approval on Linkedin Email AREXVY’s Expanded Indication Approval link